HUP9902698A2 - Humán bikunin - Google Patents

Humán bikunin

Info

Publication number
HUP9902698A2
HUP9902698A2 HU9902698A HUP9902698A HUP9902698A2 HU P9902698 A2 HUP9902698 A2 HU P9902698A2 HU 9902698 A HU9902698 A HU 9902698A HU P9902698 A HUP9902698 A HU P9902698A HU P9902698 A2 HUP9902698 A2 HU P9902698A2
Authority
HU
Hungary
Prior art keywords
proteins
serine protease
protease activity
subject
human bikunin
Prior art date
Application number
HU9902698A
Other languages
English (en)
Inventor
Gary Davis
Katherine A. Delaria
Christopher W. Marlor
Daniel K. Muller
Paul P. Tamburini
Original Assignee
Bayer Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corporation filed Critical Bayer Corporation
Publication of HUP9902698A2 publication Critical patent/HUP9902698A2/hu
Publication of HUP9902698A3 publication Critical patent/HUP9902698A3/hu
Publication of HU226419B1 publication Critical patent/HU226419B1/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114Kunitz type inhibitors
    • C07K14/8117Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/57Protease inhibitors from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114Kunitz type inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)

Abstract

A találmány tárgyát képezik szerinprőteáz-aktivitást gátló prőteinek.A találmány tárgyát képezik tővábbá a találmány szerintiszerinprőteáz-aktivitást gátló prőteinek előállítására alkalmasnűklein- sav-kőnstrűkciók, vektőrők és gazdasejtek, ilyen prőteinekettartalmazó gyógyászati készítmények, valamint eljárásők azőkalkalmazására. A találmány szerinti megőldás alkalmas számős őlyanbetegség kezelésére és megelőzésére, amelyek kialakűlásábanszerinprőteáz-aktivitás játszik szerepet. ŕ
HU9902698A 1996-03-11 1997-03-10 Human bikunin HU226419B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1310696P 1996-03-11 1996-03-11
US1979396P 1996-06-14 1996-06-14
US72525196A 1996-10-04 1996-10-04
PCT/US1997/003894 WO1997033996A2 (en) 1996-03-11 1997-03-10 Human bikunin

Publications (3)

Publication Number Publication Date
HUP9902698A2 true HUP9902698A2 (hu) 1999-11-29
HUP9902698A3 HUP9902698A3 (en) 2001-06-28
HU226419B1 HU226419B1 (en) 2008-12-29

Family

ID=27359773

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9902698A HU226419B1 (en) 1996-03-11 1997-03-10 Human bikunin

Country Status (27)

Country Link
US (3) US6583108B1 (hu)
EP (1) EP0891426B1 (hu)
JP (2) JP3469584B2 (hu)
KR (1) KR100356956B1 (hu)
AR (3) AR006188A1 (hu)
AT (1) ATE328083T1 (hu)
AU (1) AU716923B2 (hu)
BR (1) BR9708021A (hu)
CA (1) CA2247888A1 (hu)
CO (1) CO4600683A1 (hu)
DE (1) DE69735996T2 (hu)
DK (1) DK0891426T3 (hu)
ES (1) ES2263174T3 (hu)
HR (1) HRP970144B1 (hu)
HU (1) HU226419B1 (hu)
ID (1) ID16224A (hu)
IL (1) IL126115A (hu)
IN (1) IN192874B (hu)
MY (1) MY120693A (hu)
NZ (1) NZ331540A (hu)
PA (1) PA8426301A1 (hu)
PL (1) PL188387B1 (hu)
PT (1) PT891426E (hu)
SV (1) SV1997000018A (hu)
TR (1) TR199801794T2 (hu)
WO (1) WO1997033996A2 (hu)
YU (1) YU8997A (hu)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
DE69632435T2 (de) * 1995-07-24 2005-05-12 Mitsubishi Chemical Corp. Inhibitor des Hepatozytwachstumsfaktoraktivators
IL126115A (en) 1996-03-11 2007-03-08 Aerovance Inc Significantly purified protein with suppressive activity for sirin protease and its pharmaceutical preparations
AU6042298A (en) 1997-01-31 1998-08-25 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
DE69939559D1 (de) * 1998-12-22 2008-10-23 Bayer Ag Methode zur Beschleunigung der Schleimauflöserate
AU3731400A (en) 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Methods and compositions useful in inhibiting apoptosis
WO2000051623A2 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
US20040235715A1 (en) * 1999-11-12 2004-11-25 Bayer Corporation Method of producing glycosylated bikunin
IL140993A0 (en) 2000-05-15 2002-02-10 Bayer Ag Trypsin substrate and diagnostic device, and method of using same
IL140994A (en) * 2000-05-15 2005-12-18 Bayer Ag Urinary trypsin inhibitor assay containing a chelating agent
US6955921B2 (en) * 2001-04-30 2005-10-18 Bayer Corporation Trypsin substrate and diagnostic device, and method of using same
EP1539985A4 (en) * 2001-11-05 2006-06-28 Curagen Corp THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING THESE POLYPEPTIDES, AND METHODS OF USE
DK1941867T3 (da) 2002-06-07 2012-01-02 Dyax Corp Polypeptid med modificeret Kunitz domæne
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
DK1583562T3 (da) 2003-01-06 2011-09-19 Angiochem Inc Angiopep-1, beslægtede forbindelser og anvendelser deraf
US8460243B2 (en) 2003-06-10 2013-06-11 Abbott Diabetes Care Inc. Glucose measuring module and insulin pump combination
US7244616B2 (en) 2003-06-27 2007-07-17 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
US7722536B2 (en) 2003-07-15 2010-05-25 Abbott Diabetes Care Inc. Glucose measuring device integrated into a holster for a personal area network device
CA2536918A1 (en) 2003-08-26 2005-03-03 Leland Shapiro Compositions of, and methods for, alpha-1 antitrypsin fc fusion molecules
DE602004025380D1 (de) * 2003-10-10 2010-03-18 Multicell Technologies Inc Immortalisierte hepatozyten
US7419665B2 (en) * 2003-10-16 2008-09-02 Siemens Healthcare Diagnostics Inc. Monoclonal antibodies for detection of urinary trypsin inhibitors
EP1586587A1 (en) * 2004-04-16 2005-10-19 Exonhit Therapeutics SA Compositions and methods for detecting angiogenesis
CA2858901C (en) 2004-06-04 2024-01-16 Carolyn Anderson Diabetes care host-client architecture and data management system
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
ES2383901T5 (es) * 2005-02-18 2015-02-25 Angiochem Inc. Polipéptidos de aprotinina para transportar un compuesto a través de la barrera sangre-cerebro
WO2007011693A2 (en) * 2005-07-14 2007-01-25 Medistem Laboratories, Inc. Compositions of placentally-derived stem cells for the treatment of cancer
ES2424242T3 (es) 2005-07-15 2013-09-30 Angiochem Inc. Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos
US8093017B2 (en) * 2005-12-07 2012-01-10 Siemens Heathcare Diagnostics Inc. Detection of soluble adiponectin receptor peptides and use in diagnostics and therapeutics
PT1981519T (pt) * 2005-12-29 2018-02-23 Dyax Corp Inibição de protéases
WO2008034161A1 (en) * 2006-09-19 2008-03-27 Phylogica Limited Neuroprotective peptide inhibitors of ap-1 signaling and uses therefor
WO2008058167A2 (en) * 2006-11-07 2008-05-15 Case Western Reserve University Method for treating disorders associated with complement activation
WO2008077478A1 (en) * 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Preparation and use of variants of the kunitz domain 2 of the human placental bikunin gene
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
WO2008154700A1 (en) * 2007-06-20 2008-12-24 Phylogica Limited Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ards) and clinical disorders associated with therewith
JP2010536870A (ja) * 2007-08-21 2010-12-02 ジェンザイム・コーポレーション カリクレイン阻害剤を用いた治療
DE102007056231A1 (de) 2007-09-08 2009-03-12 Bayer Healthcare Ag Herstellung und Verwendung von Varianten humander Kunitz-Typ Protease-Inhibitoren (hKTPI)
JP5860698B2 (ja) * 2008-04-18 2016-02-16 アンジオケム,インコーポレーテッド パクリタキセル、パクリタキセル類似体またはパクリタキセルコンジュゲートの医薬組成物ならびに関連する調製方法および使用方法
BRPI0920209A2 (pt) 2008-10-15 2015-12-22 Angiochem Inc conjugados de agonistas de glp-1 e usos dos mesmos
RU2531591C2 (ru) 2008-10-15 2014-10-20 Ангиокем Инк. Конъюгаты этопозида и доксорубицина для доставки лекарственных средств
US9914754B2 (en) 2008-12-05 2018-03-13 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
MX2011006685A (es) 2008-12-17 2011-09-27 Angiochem Inc Inhibidores de metaloproteinas de matriz de membrana tipo-1 y sus usos.
WO2010080833A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
ES2729261T3 (es) 2009-04-20 2019-10-31 Angiochem Inc Tratamiento del cáncer de ovario utilizando un agente anticancerígeno conjugado con un análogo de Angiopep-2
IN2012DN00248A (hu) 2009-07-02 2015-05-01 Angiochem Inc
CA3168591A1 (en) 2010-01-06 2011-07-14 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins
EP2371857A1 (en) * 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
KR102502293B1 (ko) 2011-01-06 2023-02-21 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
US10136845B2 (en) 2011-02-28 2018-11-27 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
AU2012272636A1 (en) 2011-06-24 2013-05-02 Advent Bio Holdings Llc Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
AU2013202648B2 (en) 2012-01-10 2016-05-19 Konkuk University Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
EP2885318A4 (en) 2012-08-14 2016-03-30 Angiochem Inc PEPTIDE-DENDRIMER CONJUGATES AND USES THEREOF
MY178774A (en) 2014-02-24 2020-10-20 Takeda Pharmaceuticals Co Uti fusion proteins
IL295414A (en) 2014-03-27 2022-10-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema as a result of diabetes
ES2826827T3 (es) 2015-06-15 2021-05-19 Angiochem Inc Métodos para el tratamiento de carcinomatosis leptomeníngea
NZ744233A (en) 2015-12-11 2023-11-24 Takeda Pharmaceuticals Co Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
CA3174478A1 (en) 2020-03-05 2021-09-10 DiaMedica USA Inc. Ulinastatin polypeptides

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223482A (en) 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
US5106833A (en) 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
ES2066033T3 (es) 1989-05-13 1995-03-01 Bayer Ag Inhibidores de las proteinasas, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
DK408089D0 (da) 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
ES2086521T3 (es) 1990-01-25 1996-07-01 Univ Washington Proteina hibrida laci-factor x.
AU1581692A (en) 1991-03-01 1992-10-06 Protein Engineering Corporation Inhibitors of human neutrophil elastase and human cathepsin g
RU2054180C1 (ru) 1991-08-21 1996-02-10 Жирнов Олег Петрович (н/п) Способ лечения вирусных респираторных инфекций
IL104326A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104325A (en) 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
JPH07509229A (ja) 1992-07-13 1995-10-12 コルバス・インターナショナル、インコーポレイテッド ウシ膵トリプシン阻害因子から誘導される因子Xaの阻害因子
IL107831A0 (en) 1992-12-02 1994-05-30 Zymogenetics Inc Novel human amyloid protein precursor homolog and kunitz-type inhibitor
US5436153A (en) 1992-12-02 1995-07-25 Sprecher; Cindy A. Human amyloid protein precursor homolog and Kunitz-type inhibitor
JP2769083B2 (ja) 1993-02-22 1998-06-25 日清食品株式会社 エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
PT1489097E (pt) 1994-01-11 2012-01-04 Dyax Corp Inibidores de plasmina humana derivados de domínios kunitz e ácidos nucleicos codificando os mesmos
PT739355E (pt) 1994-01-11 2005-01-31 Dyax Corp Proteinas de 'dominio de kunitz' inibidoras de calicreina e seus analogos
US5795954A (en) 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
WO1996003503A1 (fr) 1994-07-21 1996-02-08 The Green Cross Corporation Procede de production d'un inhibiteur de la trypsine urinaire et des domaines de celui-ci, nouveau polypeptide associe et procede de production de ce polypeptide
US5541228A (en) * 1994-10-14 1996-07-30 Bristol-Myers Squibb Co. Melatonergic agents
WO1996035788A2 (en) 1995-05-08 1996-11-14 Scios, Inc. Kunitz type protease inhibitors
US5786328A (en) 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
DE69632435T2 (de) * 1995-07-24 2005-05-12 Mitsubishi Chemical Corp. Inhibitor des Hepatozytwachstumsfaktoraktivators
US5736364A (en) 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
IL126115A (en) 1996-03-11 2007-03-08 Aerovance Inc Significantly purified protein with suppressive activity for sirin protease and its pharmaceutical preparations
AU6042298A (en) 1997-01-31 1998-08-25 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
US6294648B1 (en) * 1999-07-20 2001-09-25 Bayer Corporation Protein having proteinase inhibitor activity

Also Published As

Publication number Publication date
CA2247888A1 (en) 1997-09-18
HRP970144A2 (en) 1998-04-30
SV1997000018A (es) 1999-01-14
YU8997A (sh) 1999-09-27
US6583108B1 (en) 2003-06-24
JP2001521367A (ja) 2001-11-06
DE69735996D1 (de) 2006-07-06
US7019123B2 (en) 2006-03-28
AR053063A2 (es) 2007-04-18
ID16224A (id) 1997-09-11
MY120693A (en) 2005-11-30
EP0891426A2 (en) 1999-01-20
AU716923B2 (en) 2000-03-09
KR19990087697A (ko) 1999-12-27
HUP9902698A3 (en) 2001-06-28
AR058982A1 (es) 2008-03-05
TR199801794T2 (xx) 2000-07-21
NZ331540A (en) 1999-10-28
ATE328083T1 (de) 2006-06-15
JP3469584B2 (ja) 2003-11-25
ES2263174T3 (es) 2006-12-01
DE69735996T2 (de) 2007-02-15
AR006188A1 (es) 1999-08-11
PT891426E (pt) 2006-10-31
DK0891426T3 (da) 2006-10-02
CO4600683A1 (es) 1998-05-08
KR100356956B1 (ko) 2003-03-15
PA8426301A1 (es) 2000-05-24
US20060172946A1 (en) 2006-08-03
EP0891426B1 (en) 2006-05-31
PL328822A1 (en) 1999-02-15
HRP970144B1 (en) 2004-10-31
HU226419B1 (en) 2008-12-29
BR9708021A (pt) 1999-07-27
WO1997033996A2 (en) 1997-09-18
AU2207797A (en) 1997-10-01
US7452859B2 (en) 2008-11-18
PL188387B1 (pl) 2005-01-31
IL126115A (en) 2007-03-08
JP2004000208A (ja) 2004-01-08
US20030194398A1 (en) 2003-10-16
WO1997033996A3 (en) 1997-11-13
IN192874B (hu) 2004-05-29
IL126115A0 (en) 1999-05-09

Similar Documents

Publication Publication Date Title
HUP9902698A2 (hu) Humán bikunin
FI925787A0 (fi) Proteolytiska enzymers sackarinderivatinhibitorer
HUP0101948A2 (hu) Il-2-szelektív agonisták és antagonisták
CA2058935A1 (en) Pharmaceutical compositions and method for treatment using alzheimer's amyloid peptides
DK0910647T3 (da) Human DNase i hyperaktive varianter
IS6194A (is) Serínprótínasar úr fiski og notkun þeirra í lyf og snyrtivörur
HUP9800075A2 (hu) Nukleinsav-konstrukciók proteázokkal aktíválható hatóanyagok expresszálására valamint előállításuk és alkalmazásuk
TR200101307T2 (tr) Antranilik asit amidler ve ilaç olarak kullanılmaları.
HUP9702377A2 (hu) Önfelerősítő, gyógyszeres úton szabályozható expressziós rendszerek
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
DE3587875D1 (de) Rekombinantverfahren zur herstellung von serinproteaseinhibitoren, sowie dns-sequenzen dazu.
Sangeetha et al. Anti-inflammatory activity of a serine protease produced from Bacillus pumilus SG2
HUP9802961A2 (hu) Kötési partner ciklinfüggő kinázok inhibitoraihoz és ezek alkalmazása inhibitorok kereséséhez, valamint egy betegség diagnózisához vagy terápiájához
NO994858L (no) Forbindelser og preparater til behandling av sykdommer assosiert med serinprotease, spesielt tryptase aktivitet
ES2170747T3 (es) Analogos superiores de trombomodulina para uso farmaceutico.
HUP9802531A2 (hu) Eljárás haematopoeticus stem sejtek mobilizálására
EP0674001A2 (en) Novel protease for treating devitalized tissue
ES8900018A1 (es) Procedimiento para la fabricacion de derivados aminoalcoholes peptidicos inhibidores de la renina y de las proteasas acidas
HUP9900789A2 (hu) Lefelé irányuló szabályozásra rezisztens C3 konvertáz
US5260060A (en) Fibrinolytic enzymes
NZ256246A (en) Serine leukocyte protease inhibitor, recombinant preparation thereof, and treatment of a retroviral infection
HUP9903892A2 (hu) Hidroxámsavszármazékok
ATE86611T1 (de) Topische vorstufen von arzneimitteln zur behandlung von akne und hautkrankheiten.
HUP0100937A2 (hu) Többszörösen elágazó peptidkonstrukciókat tartalmazó liposzómák és alkalmazásuk humán immundeficiencia vírus ellen
MXPA03010380A (es) Uso de inhibidores de la proteasa para el virus de inmunodeficiencia humana (vih) para bloquear la migracion y/o invasion de celulas, infiltracion de tejido y formacion de edema.

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: AEROVANCE, INC., US

Free format text: FORMER OWNER(S): BAYER CORPORATION, US

MM4A Lapse of definitive patent protection due to non-payment of fees